HDAC inhibitors and therapeutic methods using the same
Histone deacetylases inhibitors (HDACIs) and compositions containing the same are disclosed. Methods of treating diseases and conditions wherein inhibition of HDAC provides a benefit, like a cancer, a neurodegenerative disorder, a peripheral neuropathy, a neurological disease, traumatic brain injury, stroke, hypertension, malaria, an autoimmune disease, autism, autism spectrum disorders, and inflammation, also are disclosed.
1. A compound having a formula:
wherein A is selected from the group consisting
of —C(═O)NHheteroaryl, —NHC(═O)heteroaryl, aryl, heteroaryl, and
wherein B and C are, independently, aryl or heterocyclyl and n is 2 or 3;
or a pharmaceutically acceptable salt thereof.
2. A compound having a formula:
wherein A is selected from the group consisting
of —NHC(═O)alkyl, —NHC(═O)cycloalkyl, —NHC(═O)heteroaryl, aryl, and heteroaryl,
n is 0 or 1; and
p is 0 or 1,
or a pharmaceutically acceptable salt thereof.
3. A compound having a structure selected from the group consisting of
wherein Boc is tert-butoxycarbonyl; and Bz is benzoyl.
4. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or vehicle.
5. A compound of claim 1 wherein the compound is labeled with a fluorescent dye, a radioisotope selected from 3 H, 11 C, 18 F, 123 I, 125 I, and 131 I, a molecular tag, or a mixture thereof.
6. The compound of claim 1 wherein A is —NHC(═O) heteroaryl.
7. The compound of claim 6 wherein heteroaryl is oxazolyl.
8. The compound of claim 1 having the formula